Osiris Therapeutics (OSIR) 5.20 $OSIR IMPORTANT

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 8:01 AM

Osiris Therapeutics (OSIR) 5.20 $OSIR

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against Osiris Therapeutics, Inc. and Advises Investors to Contact the Firm
BusinessWire - Thu Jun 02, 11:49AM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(Nasdaq: OSIR). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
OSIR: 5.20 (+0.03)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company"

(NASDAQ: OSIR) concerning possible violations of federal securities laws.
OSIR: 5.20 (+0.03), MDXG: 7.59 (+0.02)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
PR Newswire - Wed Jun 01, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(NasdaqGM: OSIR -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at
OSIR: 5.20 (+0.03)

INVESTOR ALERT: Investigation of Osiris Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Tue May 31, 1:28PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(NASDAQ: OSIR) concerning the Company and its officers' possible violations of federal securities laws.
OSIR: 5.20 (+0.03)

MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
PR Newswire - Tue May 17, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has filed a lawsuit under the Lanham Act against Osiris Therapeutics, Inc. for permanent injunctive relief and damages.
OSIR: 5.20 (+0.03), MDXG: 7.59 (+0.02)

Osiris Provides Update Regarding NASDAQ Listing Matters
BusinessWire - Mon May 16, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company"

, today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market ("NASDAQ"

.
OSIR: 5.20 (+0.03), SYK: 116.62 (+0.16)

Osiris to Present at the 26th European Wound Management Association Conference
BusinessWire - Tue May 10, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the 26th European Wound Management Association Conference.
OSIR: 5.20 (+0.03), SYK: 116.62 (+0.16)

Grafix Demonstrates Superior Clinical Outcomes Compared with EpiFix in "Real World" Study
BusinessWire - Mon May 02, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company, focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announces the results of A Retrospective, Single-Center, Non-Randomized, Cross-Sectional Comparative Effectiveness Study Evaluating Surface Area Reduction, Volume Reduction and Closure Rates in Acute and Chronic Wounds Managed with Grafix(R) versus EpiFix(R).
OSIR: 5.20 (+0.03), SYK: 116.62 (+0.16)

Osiris to Present 15 Advanced Clinical and Scientific Abstracts
BusinessWire - Tue Apr 12, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) and Wound Healing Society Spring Conference, the nation's largest interdisciplinary wound care event within the clinical field.
OSIR: 5.20 (+0.03), SYK: 116.62 (+0.16)

Osiris Announces Further Expansion of Grafix Commercial Coverage
BusinessWire - Fri Apr 08, 11:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that over 52 million commercial beneficiaries are covered for Grafix(R).
OSIR: 5.20 (+0.03), SYK: 116.62 (+0.16)

Osiris Therapeutics Announces Receipt of Deficiency Letter from NASDAQ
BusinessWire - Tue Mar 22, 3:30PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it has received a letter from The NASDAQ Stock Market ("NASDAQ"

notifying the Company that it is not in compliance with NASDAQ Listing Rule 5250 (c)(1) because its Annual Report on Form 10-K for the year ended December 31, 2015 was not filed on a timely basis with the Securities and Exchange Commission.
OSIR: 5.20 (+0.03), SYK: 116.62 (+0.16)

Osiris Therapeutics Has Returned 66.5% Since SmarTrend Recommendation (OSIR)
Comtex SmarTrend(R) - Mon Mar 21, 1:05PM CDT
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on October 6th, 2015 at $16.79. In approximately 6 months, Osiris Therapeutics has returned 66.52% as of today's recent price of $5.62.
OSIR: 5.20 (+0.03)

Osiris Therapeutics to Present at the 4th Annual Cell and Gene Therapy Investor Day
BusinessWire - Fri Mar 18, 8:30AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Dwayne Montgomery, President and Chief Executive Officer, and Greg Law, Chief Financial Officer are scheduled to present at the Alliance for Regenerative Medicine's 4th Annual Cell and Gene Therapy Investor Day on Tuesday, March 22, 2016 at 10:00 a.m. ET in New York City.
OSIR: 5.20 (+0.03), SYK: 116.62 (+0.16)

Osiris Provides an Update on a Clinical Review by Blue Cross Blue Shield Association
BusinessWire - Wed Mar 16, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that the Blue Cross Blue Shield Association has provided a positive review on Grafix(R) usage for individuals with diabetic lower-extremity ulcers.
OSIR: 5.20 (+0.03), SYK: 116.62 (+0.16)

Faruqi & Faruqi, LLP is Investigating Osiris Therapeutics, Inc. (OSIR) on Behalf of its Shareholders
PR Newswire - Wed Mar 16, 2:32PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential wrongdoing at Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(NASDAQ:OSIR).
OSIR: 5.20 (+0.03)

Osiris Therapeutics Has Returned 55.9% Since SmarTrend Recommendation (OSIR)
Comtex SmarTrend(R) - Fri Mar 04, 4:33PM CST
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on October 6th, 2015 at $16.79. In approximately 5 months, Osiris Therapeutics has returned 55.91% as of today's recent price of $7.40.
OSIR: 5.20 (+0.03)

Grafix Demonstrates Positive Clinical Outcomes in Chronic Complex Wounds with Exposed Tendon and Bone
BusinessWire - Fri Mar 04, 7:00AM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today the results of its prospective, multi-center, single-arm clinical trial evaluating the clinical outcomes of Grafix(R) in patients with complex chronic diabetic foot ulcers with exposed tendon and bone.
OSIR: 5.20 (+0.03), SYK: 116.62 (+0.16)

Osiris Confirms Dwayne Montgomery, as President and Chief Executive Officer, and the Election of Thomas M. Brandt to the Board of Directors
BusinessWire - Thu Mar 03, 3:00PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is pleased to announce that its Board of Directors, at a Board Meeting on March 3rd, 2016, confirmed the appointment of Dwayne Montgomery as the President and Chief Executive Officer. He will also serve as a Director of the company and stand for re-election by the company's Stockholders at its 2016 Annual Meeting.
OSIR: 5.20 (+0.03), SYK: 116.62 (+0.16)

Shares of OSIR Down 56.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 19, 9:21AM CST
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on October 6th, 2015 at $16.79. In approximately 5 months, Osiris Therapeutics has returned 56.81% as of today's recent price of $7.25.
OSIR: 5.20 (+0.03)

Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 2:50PM CST
Dipexium (DPRX) attains 75% enrollment milestone in two phase III studies on Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 10.32 (-0.39), OSIR: 5.20 (+0.03), LGND: 113.83 (-0.16), ANIK: 50.27 (+0.10)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Revamping Children's Radiotherapy: Leo Cancer Care's Vision

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

AI Memory Growth Pushes Limits at GMIF2026 Summit

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

IASO's FUCASO Shows Robust Results in 2026 Study

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Salveo Home Care Faces Class Action Over Labor Violations

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

DKS Facing Class Action Over Stock Slump Allegations

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Quay Shines in 2026 Prescription Sunglasses Lineup

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Fuse Oncology Showcases New iRT Workflow at ASTRO

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Melrose Fire Station Reaches Steel Topping Milestone

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...